CompanyGraph
Rua Life Sciences Plc
RUA · United Kingdom
rualifesciences.comFinancials as of FY2024 · latest on file
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $20.12M, lower than 95% of all stocks globally
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2024 (year ended March 31, 2024). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
14.89MGBP20.12M · vs all stocks (USD)
Revenue (TTM)
4.62MGBP6.24M · vs all stocks (USD)
Profit Margin
6.10%vs Medical Devices peers
Beta
0.9740xvs all stocks
52-Week Change
97.94%vs all stocks
Market Capitalization
14.89MGBP20.12M · vs all stocks (USD)
Enterprise Value
13.22MGBP17.85M · vs all stocks (USD)
Forward P/E
-60.00xvs Medical Devices peers
Price to Sales (TTM)
3.23xvs Medical Devices peers
Price to Book (MRQ)
2.12xvs Medical Devices peers
Enterprise to Revenue
2.86xvs Medical Devices peers
Enterprise to EBITDA
22.99xvs Medical Devices peers
Profit Margin
6.10%vs Medical Devices peers
Operating Margin
-8.52%vs Medical Devices peers
Return on Assets (TTM)
-17.63%vs Medical Devices peers
Return on Equity (TTM)
-20.05%vs Medical Devices peers
Revenue (TTM)
4.62MGBP6.24M · vs all stocks (USD)
Revenue per Share (TTM)
0.0740GBPUpdated Aug 8, 2026Quarterly Revenue Growth
6.10%vs Medical Devices peers
Gross Profit (TTM)
3.61MGBP4.88M · vs all stocks (USD)
EBITDA (TTM)
575.00KGBP776.56K · vs all stocks (USD)
Net Income (TTM)
281.67KGBP380.40K · vs all stocks (USD)
Operating Cash Flow (TTM)
-899.67KGBP-1.22M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-1.44MGBP-1.94M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00GBPUpdated Aug 8, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
2.19MGBPFY2024 · Mar 31, 2024Cost of Goods Sold
415.00KGBPFY2024 · Mar 31, 2024Gross Profit
1.78MGBPFY2024 · Mar 31, 2024Operating Income
-1.95MGBP-2.64M · vs all stocks (USD)
Pre-tax Income
-2.02MGBPFY2024 · Mar 31, 2024Income Tax Expense
-580.00KGBPFY2024 · Mar 31, 2024Net Income
-1.44MGBPFY2024 · Mar 31, 2024EBIT
-1.95MGBPFY2024 · Mar 31, 2024EBITDA (Income Statement)
-1.59MGBPFY2024 · Mar 31, 2024Research & Development
873.00KGBPFY2024 · Mar 31, 2024Selling, General & Administrative
1.16MGBPFY2024 · Mar 31, 2024EPS (Basic)
-0.0429GBPFY2024 · Mar 31, 2024EPS (Diluted)
-0.0429GBPFY2024 · Mar 31, 2024Basic Shares Outstanding
62.06MSharesFY2024 · Mar 31, 2024Diluted Shares Outstanding
62.06MSharesFY2024 · Mar 31, 2024Net Income from Continuing Operations
-1.44MGBPFY2024 · Mar 31, 2024Minority Interests (P&L)
0.00GBPFY2024 · Mar 31, 2024Preferred Stock Dividends
0.00GBPFY2024 · Mar 31, 2024Operating Cash Flow
-1.78MGBPFY2024 · Mar 31, 2024Free Cash Flow
-1.81MGBPFY2024 · Mar 31, 2024Cash & Cash Equivalents (End of Period)
3.93MGBPFY2024 · Mar 31, 2024Starting Profit (CF Statement)
-1.44MGBPFY2024 · Mar 31, 2024Stock-based Compensation
-35.00KGBPFY2024 · Mar 31, 2024Other Non-cash Items
83.00KGBPFY2024 · Mar 31, 2024Change in Accounts Receivable (CF)
-362.00KGBPFY2024 · Mar 31, 2024Change in Other Assets/Liabilities
-31.00KGBPFY2024 · Mar 31, 2024Capital Expenditures
-30.00KGBPFY2024 · Mar 31, 2024Net Investing Cash Flow
-30.00KGBPFY2024 · Mar 31, 2024Long-term Debt Issuance
7.00KGBPFY2024 · Mar 31, 2024Long-term Debt Payments
-93.00KGBPFY2024 · Mar 31, 2024Net Financing Cash Flow
3.89MGBPFY2024 · Mar 31, 2024Shares Outstanding
62.06MSharesUpdated Aug 8, 2026Float Shares
50.42MSharesUpdated Aug 8, 2026% Held by Insiders
19.16%vs all stocks
% Held by Institutions
17.58%vs all stocks
Total Cash (MRQ)
2.37MGBP3.19M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0380GBPUpdated Aug 8, 2026Total Debt (MRQ)
651.00KGBP879.20K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0925xvs Medical Devices peers
Current Ratio (MRQ)
5.92xvs Medical Devices peers
Book Value per Share (MRQ)
0.1130GBPUpdated Aug 8, 2026Total Assets
8.17MGBP11.03M · vs all stocks (USD)
Total Current Assets
4.99MGBPFY2024 · Mar 31, 2024Total Liabilities
987.00KGBPFY2024 · Mar 31, 2024Total Non-current Assets
3.18MGBPFY2024 · Mar 31, 2024Total Non-current Liabilities
433.00KGBPFY2024 · Mar 31, 2024Total Current Liabilities
554.00KGBPFY2024 · Mar 31, 2024Cash
3.93MGBPFY2024 · Mar 31, 2024Cash & Cash Equivalents
3.93MGBPFY2024 · Mar 31, 2024Accounts Receivable
301.00KGBPFY2024 · Mar 31, 2024Inventory
112.00KGBPFY2024 · Mar 31, 2024Accounts Payable
140.00KGBPFY2024 · Mar 31, 2024Short-term Debt
117.00KGBPFY2024 · Mar 31, 2024Long-term Debt
272.00KGBPFY2024 · Mar 31, 2024Common Stock (Book)
3.10MGBPFY2024 · Mar 31, 2024Retained Earnings
-19.98MGBPFY2024 · Mar 31, 2024Total Shareholders' Equity
7.18MGBP9.70M · vs all stocks (USD)
52-Week Low
10.42GBXUpdated Aug 8, 202652-Week High
27.00GBXUpdated Aug 8, 202652-Week Change
97.94%vs all stocks
Beta
0.9740xvs all stocks
50-Day MA
21.23GBXUpdated Aug 8, 2026200-Day MA
16.43GBXUpdated Aug 8, 2026Avg 10-Day Volume
92.38KSharesUpdated Aug 8, 2026Avg 30-Day Volume
150.30KSharesUpdated Aug 8, 2026Diluted EPS (TTM)
-0.0429GBPUpdated Aug 8, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $20.12M, lower than 95% of all stocks globallySignificant
Market cap (USD): 20,115,422.195Global P5: 269,387,740.27
Revenue is $6.24M, lower than 95% of all stocks globallySignificant
Revenue (USD): 6,235,850.788Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Aptamer Group Plc
Tier 1ProductionApproval-Gated PipelineRule
Inspiration Healthcare Group plc
Tier 1ProductionApproval-Gated PipelineRule
BioLineRx Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Genflow Biosciences Plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
ImmuPharma PLC
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cizzle Biotechnology Holdings Plc
Tier 1ProductionApproval-Gated PipelineRule
SkinBioTherapeutics Plc
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Crism Therapeutics Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sailong Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Context Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Jiangsu Hengli Hydraulic Co., Ltd.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Halo Microelectronics Co., Ltd.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets